GlassScriptPhysician profile
Matthew James Sheldon
NPI 1790919728
$5,880.90
in general payments reported to CMS, 2019-2025
43 companies · $856 in 2025
The $856 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,068 · 2020: $495 · 2021: $813 · 2022: $925 · 2023: $1,004 · 2024: $719 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,579.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,207.22 | 2019-2025 | Botox, Lupron Depot |
| Astellas Pharma US INC | $901.79 | 2019-2025 | Xtandi, Myrbetriq |
| Pfizer INC. | $679.78 | 2019-2025 | |
| Janssen Biotech, INC. | $377.86 | 2019-2025 | Erleada |
| Sumitomo Pharma America, INC. | $343.46 | 2023-2025 | Gemtesa, Orgovyx |
| Caldera Medical, INC | $241.35 | 2022-2023 | Desara |
| Ferring Pharmaceuticals INC. | $205.87 | 2019-2025 | Adstiladrin |
| Merck Sharp & Dohme LLC | $162.31 | 2020-2024 | Welireg, Keytruda, Lynparza |
| Dendreon Pharmaceuticals LLC | $140.73 | 2019-2024 | Provenge |
| Allergan, INC. | $136.19 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $118.26 | 2020-2023 | Lynparza |
| Endo Pharmaceuticals INC. | $113.19 | 2019-2023 | Edex, Aveed, Xiaflex |
| Amgen INC. | $97.06 | 2019-2020 | |
| Teleflex LLC | $86.37 | 2021-2024 | Urolift |
| Bayer Healthcare Pharmaceuticals INC. | $85.06 | 2019 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Sheldon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.